LOH analysis should not be used as a tool to assess whether UVs of BRCA1/2 are pathogenic or not

Author： Beristain E.   Guerra I.   Vidaurrazaga N.   Burgos-Bretones J.   Tejada M.  

Publisher： Springer Publishing Company

ISSN： 1389-9600

Source： Familial Cancer, Vol.9, Iss.3, 2010-09, pp. : 289-290

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis

By  

The Women's Oncology Review, Vol. 4, Iss. 3, 2004-09 ,pp. : 201-203

Informa Healthcare

Access to resources Recommend Favorite

Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 115-116

Informa Healthcare

Access to resources Recommend Favorite

Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families

By                

International Journal of Oncology, Vol. 41, Iss. 5, 2012-01 ,pp. : 1619-1627

Spandidos Publications

Access to resources Recommend Favorite

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

By Györffy Balazs  

Breast Cancer Research and Treatment, Vol. 123, Iss. 3, 2010-10 ,pp. : 725-731

Springer Publishing Company

Access to resources Recommend Favorite

LOH analysis of free DNA in the plasma of patients with mucosal malignant melanoma in the head and neck

By Takagi Ryo   Nakamoto Daisuke   Mizoe Jun-etsu   Tsujii Hirohiko  

International Journal of Clinical Oncology, Vol. 12, Iss. 3, 2007-06 ,pp. : 199-204

Springer Publishing Company

Access to resources Recommend Favorite